Breast Cancer, Lumpectomy, Mastectomy, Segmental
Conditions
Keywords
Breast Cancer, Lumpectomy, Mastectomy, Segmental
Brief summary
The investigators will assess changes in breast appearance, graft retention and quality of life over one year in patients who have received direct autologous adipose tissue injection for the treatment of objectionable post-surgical breast deformities. These patients have undergone the resection of breast tissue to treat either benign or malignant breast disease.
Detailed description
During the past decade there has been increased awareness of the potential of free adipose cell grafting to treat a variety of problems in both reconstructive and cosmetic plastic surgery. There have been encouraging reports describing the use of autologous fat grafts (fat tissue harvested by standard liposuction techniques in a given patient and then re-injected at another site) for treating breast deformities in the setting of benign and previously treated malignant breast problems. There has been a corresponding large scale laboratory investigation effort into the potential of adipose derived stem cells (ADSC's) harvested during liposuction and induced to differentiate into various cell types in the mesenchymal cell line. The potential clinical utility of these cells in the treatment of patients who present with a breast deformity after segmental mastectomy (lumpectomy) and radiation therapy has been described, but not studied in rigorous prospective manner. The investigators believe that the clinical use of these autologous fat cell grafts have unique advantages in the treatment of breast deformities. The technique is minimally invasive, easily repeated and is associated with minimal surgical morbidity (indeed it may have the advantage of improving the appearance of both the breast deformity and the area from which they are harvested), it typically displays a rapid recovery, a complication rate that is no greater (and probably less than ) established and currently used surgical treatment(s) of these breast problems, and is oncologically safe.
Interventions
PROCEDUREAutologous Fat Graft
Participants will receive an autologous fat graft to correct either a benign breast deformity or a post segmental mastectomy deformity.
Sponsors
University of Pittsburgh
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* Age 18 through 70 years of age inclusive and able to provide informed consent and * Subject is 6 months post chemotherapy or radiation treatment and is scheduled for physician evaluation for a standard of care breast fat graft procedure. * Per PI's discretion is stable post-surgery or who has a benign breast deformity or post segmental breast deformity * Willing and able to comply with the study schema for research procedures.
Exclusion criteria
Age less than 18 years * Inability to provide informed consent * Active chemotherapy or radiation therapy treatment for cancer diagnosis * Not clinically stable to have a surgical intervention * Active infection anywhere in the body * Known coagulopathy * Pregnancy * Per the PI's discretion, subject is not a candidate for participation in this clinical trial.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Breast Tissue Volume/Appearance (Graft Retention) | Through 12 months following procedure | Assess breast appearance and soft tissue volume before and after autologous fat grafting utilizing 2D / 3D digital photography and a physician rating scale to determine graft retention through 12 months following fat grafting procedure. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Patient Satisfaction | 6 months after procedure | Measure patient satisfaction with use of quality of life questionnaires (SF-36 and BREAST-Q) before and after autologous fat grafting. |
Other
| Measure | Time frame | Description |
|---|---|---|
| Assess Cellular Properties of Graft | Sample collected at time of procedure | Preadipocyte yield: The number of cells isolated per gram of adipose tissue will be determined using a hemacytometer. Preadipocyte Viability: Cell viability will be determined using the Live/Dead assay. Preadipocyte Proliferation: Cellular proliferation of preadipocytes will be assessed with the CyQUANT Cell Proliferation Assay Kit (Invitrogen, Carlsbad, CA) at 48 and 96 hours. Preadipocyte Differentiation: The assessment of the potential of the preadipocytes to differentiate into adipogenic cell types will be assessed |
Countries
United States
Outcome results
None listed